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A B S T R A C T
Objectives: Considerable efforts have been devoted so far to improve salvage procedures of infected
breast implants in absence of deﬁned guidelines or validated clinical protocols. Within a cohort of
prospectively recruited patients who underwent breast reconstruction, we performed a retrospec-
tive review of proven implant infections in order to describe factors contributing to management
success.
Methods: We collected data in 1293 consecutive patients who underwent two stage (expander +
prosthesis) breast reconstruction with at least 12 months of follow-up. Demographic data, timing of
infection, type of microorganism, intent of salvage, fate of the implant, type of antibiotic treatment and
follow-up were recorded in a prospective data collection on clinical records.
Results: Implant infections occurred in 103 of 1293 patients (8%). Among these, 73 (71%) were proven
infections with conﬁrmed microbiology. Implant pocket salvage was attempted in 43/73 (59%). patients
A higher proportion of expander implant pockets were successfully saved compared to prosthetic pocket
(p = 0,04). Gram-positive microrganisms represented the majority of etiologic agents, with coagulase
negative staphylococci prevailing over Staphylococcus aureus. No association was observed between
success rate and type of infecting microorganism. A higher proportion of patients with previous or
intraoperative radiotherapy or with perioperative chemotherapy underwent an attempt of implant
salvage (p = 0,081 and 0,0571 trend, respectively). No single antibiotic regimen was superior to the others
in terms of success rate. Implant pocket salvage was higher in expanders compared to prostheses (74% vs
33% p = 0,04). Higher success rates in implant pocket salvage were evident when implant replacement
was preceded and followed by antibiotic treatment compared to inpatient antibiotic treatment alone
(100% versus 57%, p = 0,035).
Conclusion: Patient selection in clinical practice leads to differences in patients with breast implant
infection who are considered for attempts at implant salvage vs. those who are treated with implant
removal. Salvage of breast implant pockets can be obtained in the majority of patients with combined
one-step implant replacement surgery and antibiotic treatment. Increased efforts and protocols to
recruit patients into pocket salvage management are needed.
© 2018 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
Introduction
Implant-based breast reconstruction is the most common
surgical option for women with breast cancer and post-
mastectomy breast defects. Among a long list of possible
postoperative complications (Georgiade et al., 1982; Schuster
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et al., 1990; Pusic and Cordeiro, 2003), implant infection
represents a devastating event for the patient and a discouraging
situation for the surgeon. Infection after implant-based recon-
struction occurs at a mean rate of 8% (1–35%) and may vary
according to clinical setting and type of procedure (Armstrong
et al., 1989; Cordeiro and McCarthy, 2006; Nahabedian et al.,
2003; Spear et al., 2004; Franchelli et al., 2015).
Over recent years, a consistent clinical focus targeted risk
factors associated to post-implant infection, causative micro-
organisms isolated from infected implants (Brand, 1993; Rieger
et al., 2013; Reish et al., 2013; Momoh et al., 2014; Kronowitz and
Robb, 2009), and prevention (Barr et al., 2016). Once breast implant
infection is detected, there is general clinical agreement that
antibiotic treatment should be provided and, most importantly,
that attempts should be made to ultimately salvage the implant.
There is a considerable degree of disagreement, however, on the
deﬁnition of implant salvage and on standardized clinical
management. Indeed, “implant salvage” this may include salvage
either of the aesthetic reconstructive result (Rieger et al., 2013;
Spear and Seruya, 2010), of the implant pocket, or of the original
implant itself (Wilkinson et al., 1985).
Similarly widely diverging views and clinical approaches exist
on optimal clinical management aiming at implant salvage.
Standard management of breast implant infection combines
implant removal with antibiotic treatment followed by delayed
positioning of a new implant weeks-months after antibiotic
treatment of the previous infected pocket (Armstrong et al.,
1989). This approach requires multiple surgical procedures (e.g., 1
removal, 1 insertion) with proportionally increased associated
risks and costs. In addition, in some of these instances, the delayed
implant re-insertion may be technically more difﬁcult due to
pocket resorption and tissue ﬁbrosis (Reish et al., 2013).
Considerable effort has been devoted to improve salvage
procedures minimizing the waiting time between implant
removal and reimplantation. Several protocols proposed by North
American and European groups may allow tissue debridment and
implant replacement during the same surgical procedure
including systemic empiric antibiotic therapy with wound
drainage (Courtiss et al., 1979), pre- and postoperative antibiotic
therapy with capsulotomy wound irrigation and implant replace-
ment (Weber and Hentz, 1986) or irrigation of implant pocket
with saline solution combined with antibiotic therapy and
implant exchange with or without capsulectomy (Chun and
Schulman, 2007; Laveaux et al., 2009; Prince et al., 2012; Missana
et al., 2012). The mentioned series are uncontrolled studies on a
mix of proven and possible infections (i.e. without microbiolog-
ical isolation) with overall limited number of patients and with
highly variable and sometimes limited follow-up (i.e., 1–6
months).
When considering actual infections, Staphylococci are the
predominant cause of breast implant infection. Empiric initial
treatment is based on this fact and on the relative local prevalence
of methicillin-resistant staphylococci. Gram negative microorgan-
isms are detected in a minor proportion of cases, are addressed by
current guidelines for SSI (surgical site infection) prophylaxis
(Berrios-Torres et al., 2017) and, when present may be associated
with lower rates of device salvage (Spear and Seruya, 2010;
Franchelli et al., 2012).
In view of the present paucity of structured indications for
management and treatment and of the need to improve our clinical
approach to patients with reconstructive breast implant infection,
we performed a retrospective review on breast implant infections
and of implant salvage procedures at our center. This analysis
shows that there are discrepancies in patient selection and in
outcome when an unstructured approach of antibiotic treatment
and surgery is active.
Patients and methods
Between February 1st 2009 and June 30st 2015, 1293
consecutive patients underwent two-stage (expander + implant)
immediate or delayed implant reconstruction after mastectomy or
implant replacement at the Policlinico San Martino in Genoa.
Clinical data of all patients at our institution are kept on record.
Written signed consent for data use for clinical purposes was
obtained from all the patients, according to approved institutional
policy. The present work is a retrospective elaboration of
institutional record data.
Implant infectionwas deﬁned as previously described (Franchelli
et al., 2012). Brieﬂy, criteria for possible infection included: fever,
minimal local edema and inﬂammation; probable infection was
deﬁned by cellulitis, leukocytosis, systemic inﬂammation, echo-
graphic evidence of inﬂammation or peri-prosthetic liquid accumu-
lation without microorganism isolation. Proven infections are
deﬁnedby the presence of purulent discharge and/or microorganism
isolation in addition to other clinical signs. Implant infections are
further subdivided into “early” (<60 days from surgery, DFS) and
“late” (>60 DFS) infections (Franchelli et al., 2015).
Patients were censored at a post-operative follow-up of at least
12 months, in order to include late infections (i.e. occurring >180
DFS).
All patients underwent surgery by the same surgical team. The
same type of expander and prosthesis was used (Allergan, Marlow
International, Parkway, United Kingdom). Expanders and prosthe-
ses had the same textured surface (Biocell: Allergan, Marlow
International, Parkway, UK) and external envelope structure
(Intrashiel: Allergan, Marlow International, Parkway, UK) made
by three overlapped layers of silicone rubber. Expanders were
positioned in a submuscular pocket after mastectomy, and
progressively inﬂated; prostheses were positioned as a replace-
ment of a previous expander after its inﬂation or during a
contralateral augmentation mammaplasty. Antibiotic prophylaxis
using Cefazolin 14–20 mg/kg (1 g followed by 2 doses q8 h) was
always administered. In patients allergic to beta-lactams (surgeons
ASop, 2018; Phillips et al., 2016) Clindamycin was used.
The following patient data were collected: age, tumor stage and
recurrence, chemo/radio–therapy, type of implants, timing and
clinical appearance of infection, type of microorganism, intent of
pocket salvage, fate of the implant (removal or salvage), type of
antibiotic treatment, follow-up after implant salvage.
We deﬁned as “perioperative chemotherapy” any chemothera-
py performed around breast reconstruction surgery either before
or after the procedure.
Standard management options for patients with proven
implant infection were: (i) implant removal and antibiotic
treatment, (ii) attempt of implant pocket salvage with antibiotic
treatment alone, (iii) combined implant replacement. Implant
removal without any pocket salvage attempt is considered at our
Center whenever at least one of the following conditions is
present: implant exposure following cutaneous subcutaneous
necrosis, cutaneous ﬁstula, extensive inﬂammation with intense
redness, pain and edema involving !3 breast quadrants.
Clinical record analysis was used to identify all those patients
who were considered for an attempt of implant pocket salvage
(“intent of salvage”). Patients for whom no prospective intent was
stated in the clinical record were deﬁned as “salvage intent
unknown” and were included in the group “no intent of salvage”
(Figure 1).
Successful salvage of the surgical implant was deﬁned as
retention of the implant for !12 months after surgery. Cultures
from multiple sites including wound, drainage ﬂuid, peri-
prosthetic seroma, capsular tissues and the prosthetic material
itself, when removed, were performed to identify the infecting
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pathogens. Susceptibility testing was performed using the Vitek 2
AES automated system (bioMerièux, Marcy-l’etoile (France) and
interpreted according to EUCAST standards (EUCAST, 2018).
Antibiotic treatment was administered for 10–12 days. When
combined with debridement and implant replacement (Antibiotic
treatment and Implant Replacement, AIR) based on available
microbiological isolate sensitivity, surgery for implant replace-
ment was performed 3–4 days after onset of antibiotic treatment.
Surgical procedures during combined salvage management
included capsular debridment up to capsulectomy, depending on
breast tissue thickness, and implant pocket irrigation with saline
solution. A complete exchange of surgical instruments/towels and
surgical coats was performed during the procedure before implant
replacement accompanied by patient disinfection.
To evaluate group differences, statistical analysis was per-
formed employing two-sided tests as required (JMP 10.0 Statistical
software, SAS Institute Inc. Mann). Chi-square analysis, Fisher’s
exact test and Mann–Whitney test were performed as appropriate
to test for differences between groups.
Results
Patient management and salvage attempts.
Implant infections were observed in 103 of 1293 patients (8%).
Among these patients, 73 (71%) had proven infections (PI) (Figure
1). Patients without microbiologically conﬁrmed infection were
excluded from further analysis since management and clinical
outcome in these cases cannot be linked to a speciﬁc microorgan-
ism(s) or to true infection. We next analyzed the clinical
management of these 73 patients with microbiologically con-
ﬁrmed PI. Implant pocket salvage attempts were performed in 43
of 73 patients (59%), while 30 cases (41%) underwent implant
removal followed by antibiotic treatment due to extensive cellulitis
and/or overwhelming breast implant infection (Figure 1). No
associations were detected between age, tumor stage, type of
implant and infection staging deﬁned both as time after surgery
and as type of infection based on microbiological identiﬁcation
(Table 1). A higher proportion of patients with previous or
Figure 1. Therapeutic management in early and late infections.
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intraoperative radiotherapy (IORT) or perioperative chemotherapy
underwent an attempt of breast implant pocket salvage (p = 0,081
and p = 0,0571 trend, respectively).
Outcome of salvage attempts according to patient characteristics and
to microbiological isolate
We next stratiﬁed patients according to the outcome (success
vs. failure) of clinical management in those who underwent clinical
attempts at implant pocket salvage. As shown in Table 2, there was
no association between outcome and age, tumor stage, relapse and
radio- or chemotherapy nor with time of infection after surgery
(early vs late infections). A higher proportion of expander implant
pockets were successfully saved compared to prosthetic pocket
(p = 0,04). This difference was independent from the onset of
infection after surgery both in terms of early vs late onset with a
limit set at 60 days from surgery (Table 2) as well as in terms of
absolute number of days from surgery to infection (p = 0,161n.s.)
Among 85 microbiological isolates obtained from 73 patients
with PI, the vast majority were Gram positive microorganisms
(83%). As shown in Figure 2 staphylococcal infections largely
prevailed over Gram negative infections (65/85, 76,5% vs 13/85,
15,3%). Among thesestaphylococci, 49% were represented by
methicillin sensitive cocci. Higher proportions of coagulase
negative cocci compared to Staphylococcus aureus, (43% vs 34%,
respectively) were isolated from capsular tissue and peri-
prosthetic ﬂuid.
Clinical management and outcome of infection
In order to verify whether successful treatment of breast
implant pocket could be associated to the type of causative
microorganism we next stratiﬁed the isolates by treatment
outcome.
Among staphylococcal infections a trend towards a higher rate
of successful salvage was recorded for Coagulase Negative
Staphylococci when compared to S. aureus infections with 18/36
vs 8/29 successful treatments, respectively (p = 0,0798). In addition
a much lower proportion of infections were due to MRSA when
compared to MSSA (3,5% vs 30,6%).
These data conﬁrm previous observations showing Staphylo-
cocci (Brand,1993; Barr et al., 2016) as the main aetiologic agents in
breast implant infections, albeit these reports had higher
proportions of S. aureus. Here, indeed, a prevalence of Coagu-
lase-negative staphylococci over S. aureus emerges and conﬁrms
previous reports at our clinical site (Armstrong et al., 1989;
Franchelli et al., 2015).
Since factors associated to the outcome of an infection may be
related to the host, to the microorganism or to the choice of
antibiotic/clinical management, we next studied the antibiotic
regimens administered to the patients together with their surgical
management. Overall, a high number of different antibiotic
regimens, according to the choice of molecule(s), dosage and
duration of administration that were administered to the 43
patients for whom an attempt of implant salvage was performed.
Eight of these patients also underwent combined surgical
replacement of the implant (Figure 1). Antibiotic regimens were
grouped into 4 groups based on antibiotic class composition and
are shown in Table 3. While none of these 4 regimens was superior
to the others in terms of implant salvage success rate, a
signiﬁcantly higher proportion of success was detected when
the clinical management that included systemic antibiotic
administration and surgical removal (AIR) was compared to
antibiotic treatment alone (8/8,100% vs 20/35, 57%respectively,
p = 0,035).
Discussion
The present work analyzes the management of proven infected
implant-based breast reconstructions and treatment strategies in a
single-center unit within the frame of everyday clinical practice
after stratiﬁcation of outcome (salvage vs. failure) to retain implant
pocket.
Proven infections represented the majority of all the infections
cared for (71%). A relevant proportion of patients with PI (n 30 or
Table 1
Demographic data of proven breast implant infections.
Proven
Infections (n = 73)
Salvage intent
Signiﬁcance
Tot
N
No
N (%)
Yes
N (%)
N" 73 30 43
Mean age 54 52 55 ns
Stage 0 3 3 (10) 0 ns
Stage 1 10 2 (7) 8 (19) ns
Stage 2 19 7 (23) 12 (28) ns
Stage 3 18 10 (34) 8 (19) ns
Unknown stage 4 1 (3) 3 (7)
Relapse or recurrence 19 7 (23) 12 (28) ns
Radiotherapy (1) 26 6 (20) 22 (51) P = 0,0081
Chemotherapy (2) 41 21 (70) 20 (46) P = 0,0577
Expander 61 27 (90) 34 (79) ns
Prosthesis 12 3 (10) 9 (21) ns
Early infection 49 19 (64) 30 (70) ns
Late infection 24 11 (37) 13 (30) ns
Probable infection 0 0 0
Proven infection 73 30 (100) 43 (100)
(1) Previous or intraoperative; (2) Perioperative Chemotherapy (pre-infection); n.s.:
not signiﬁcant; Tot: total; (%) proportion of patients with a given parameter
according to salvage intent.
Table 2
Clinical parameters in patients with proven infections who underwent salvage
attempts of implant pocket according to infection outcome.
All infections Success Failure Signiﬁcance
N" 43 43 28 (65) 15 (35)
Mean age 57 52 ns
Stage 0 0 0 0
Stage 1 8 6 (75) 2 (25) ns
Stage 2 12 9 (75) 3 (25) ns
Stage 3 8 4 (50) 4 (50) ns
Unknown stage 3 2 (67) 1 (33)
Relapse or recurrence 12 7 (58) 5 (42) ns
Radiotherapy (1) 22 12 (55) 10 (45) ns
Chemotherapy (2) 20 13 (65) 7 (35) ns
Expander 34 25 (74) 9 (26) P: 0,04
Prosthesis 9 3 (33) 6 (67)
Early infection 30 22 (73) 8 (27) ns
Late infection 13 6 (46) 7 (54) ns
(1) Previous or intraoperative radiotherapy; (2) Perioperative Chemotherapy (pre-
infection); n.s.: not signiﬁcant.
Figure 2. Proportionofsavedimplantpocketsstratiﬁedbycausativemicroorganisms.
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41%) did not undergo an attempt to rescue the implant, and were
managed with immediate implant removal and antibiotic treat-
ment. We observed that exclusion from pocket salvage attempts
was associated with current chemotherapy, while the reverse was
observed for radiotherapy. Therefore, in addition to the local extent
of the infection the need to undergo chemotherapy early after
breast reconstruction represents a compelling element that
conditions clinical management of these patients. Accordingly,
the need for chemotherapy after breast implant-based reconstruc-
tion not only represents an established risk factor for infection
(Reish et al., 2013; Yii and Khoo, 2003), but also negatively affects
the subsequent management once breast implant infection occurs.
When considering the group of patients who were managed
with an attempt at implant pocket salvage an overall success rate of
65% was recorded. It should be noted that we included also patients
with implant skin exposure and also excluded unproven infections
to avoid a bias of overstating the effect of treatment in sterile sites
(Spear and Seruya, 2010; Chun and Schulman, 2007; Prince et al.,
2012; Missana et al., 2012). Therefore, the observed overall rate of
implant pocket salvage is encouraging compared to other reports
(Spear and Seruya, 2010; Bennett et al., 2011) and represents a
positive outlook for everyday practice in proven implant infections.
Interestingly within this frame, a signiﬁcantly increased success
rate was recorded (100% vs. 57%), when combined antibiotic
treatment and implant replacement (AIR) was compared with
systemic antibiotics treatment alone. This higher success rate
compared better to other reports (Spear and Seruya, 2010; Yii and
Khoo, 2003; Bennett et al., 2011; Albright et al., 2016; Meybodi
et al., 2015).
When compared to more invasive management (e.g. removal
and delayed reconstruction) requiring repeated hospitalization,
AIR has the advantage of decreased hospitalization, decreased
surgical procedures (1 procedure vs. repeated procedures), and
may allow for the prosecution of chemotherapy. Indeed successful
infected implant salvage with AIR just anticipates the positioning
of the deﬁnitive prosthesis/implant without additional medical
and economic burdens.
In view of the greater success rate in implant pocket salvage,
which was observed for attempts performed on expanders as
compared to deﬁnitive prosthetic devices and unrelated to an
increased exposure to CT or RT, earlier referral or self-referral or
close follow-up of patients with prosthetic devices could be
advised.
In line with other series (Spear and Seruya, 2010; Chun and
Schulman, 2007) we here detected a wide spectrum of microbio-
logical ﬂora in infected implants including anaerobes, Gram
negative rods, S. aureus and coagulase negative Staphylococci.
Isolates were not associated to different rates of salvage failure. A
comparable success rate of treatment was observed for Staphylo-
coccus epidermidis infections (both methicillin sensitive and
resistant) compared to S. aureus. Overall, however, coagulase
negative Staphylococci represented signiﬁcantly more common
infecting agent compared to S. aureus in agreement with previous
reports (Franchelli et al., 2015; Prince et al., 2012). Methicillin
resistance was not a factor negatively affecting the possibility to
rescue the implant pocket and successfully treat the patient. This is
in contrast to previous reports (Prince et al., 2012; Bennett et al.,
2011), where however a very high number (33–70%) of unproven
infections were included, thus possibly overestimating failures in
the presence of methicillin resistant cocci. In view of the high
proportion of isolates from proven infections that were not
covered by the antimicrobial spectrum of the prophylactic
antibiotics, the recommendation for a change of antibiotic agent
may be indicated according to previous observations and current
recommendations (Berrios-Torres et al., 2017; Feldman et al.,
2010). The limited number of Gram negative infections (18%), on
the contrary, may not need additional changes in prophylactic
treatment, but rather should be considered for guiding initial
empiric treatment with culture results pending.
None of the antibiotic regimens evaluated here showed any
outcome advantage, in line with the wide dispersion of treatments
and with the design of the study that was not suited to the purpose.
Since there are to our knowledge no studies or recommendations
on antibiotic treatment in patients with breast implant infection
(Phillips et al., 2016; Feldman et al., 2010), this identiﬁes the need
for clinical focus in future work.
According to the present observations of high rates of MRSE and
Coagulase-negative Staphylococci and of possible Gram negative
presence, empiric treatment pending cultures of surgical samples
could best include piperacillin/tazobactam and an anti-staphylo-
coccal agent active on Coagulase negative Staphylococci and MRSA.
The present analysis is limited by its retrospective and
uncontrolled design. Controlled studies using standardized clinical
management will be needed to verify the present observations. On
the other hand, the present limits and bias also provide a useful
insight into the pitfalls of unstandardized clinical practice and
outline the need for a more standardized approach to clinical
management of breast implant pocket infections in cancer
patients. On the other hand, even with these limitations, the
study has the novelty of addressing some points that have been so
far neglected in clinical practice. There is a general lack of
comprehensive analyses on the actual management of these
patients in everyday life in conditions where structured manage-
ment, advice or speciﬁc protocols are not available. In this respect
the present data represent a ﬁrst-in-kind with several points of
novelty over previous experience on identiﬁcation and manage-
ment of infected breast implants. Indeed the present study far from
representing a single-surgeon series, includes all the patients that
were sequentially seen at a single large center by a team of
independent reconstructive surgeons. The study uses a careful
classiﬁcation of infection, includes only microbiologically proven
infections in the analysis, and performs for the ﬁrst time a detailed
analysis of everyday management decisions and outcome.
In conclusion, based on the present analysis, implant pocket
salvage of proven implant infections after breast reconstruction
represents a possible option for the majority of patients. Future
Table 3
Comparison between implants saved using antibiotic therapy plus implant replacement and implants saved using antibiotic therapy alone.
Success Failure Signiﬁcance
Antibiotic Antibiotic and replacement Antibiotic Antibiotic and replacement
blactam # inhibitor o # clindamicin 13 1 6 0 ns
Glycopeptide # rifampicin/trimethoprim-sulfamethoxazole 3 1 3 0 ns
Levoﬂoxacin 1 1 0 0 ns
Daptomicin + rifampicin 3 5 6 0 ns
Total 20 8 15 0 p = 0,035
NS: not signiﬁcance.
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prospective work will be needed to avoid clinical bias in
recruitment of eligible patients and to further improve and
simplify treatment protocols.
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